Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies

Cancer Letters

Volumn 399, Issue , 2017, Pages 44-52

  Hoseini, Sayed Shahabuddin ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bispecific antibody; Chimeric antigen receptor; Hepatocellular carcinoma; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; AMG 110; AMYLASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BISPECIFIC ANTIBODY; BLINATUMOMAB; CATUMAXOMAB; CHIMERIC ANTIGEN RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; ERY 974; GLYPICAN 3; LENTIVIRUS VECTOR; MT 110; NIVOLUMAB; OSTEOPONTIN; PEMBROLIZUMAB; RETROVIRUS VECTOR; SOLITOMAB; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VIRUS ANTIGEN; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; BREAST CANCER; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GLIOMA; HUMAN; LIVER CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; RASH; SHORT SURVEY; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; STOMACH CANCER; T LYMPHOCYTE; ADVERSE EFFECTS; ANIMAL; ANTIBODY SPECIFICITY; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 85018653357     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.04.013     Document Type: Review

References (119)

1. [1] Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, N. Engl. J. Med., 374 (2016) 998.
2. [2] Adusumilli, P.S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med., 6, 2014 261ra151.
3. [3] Affo, S., Yu, L., Schwabe, R.F., The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu. Rev. Pathol., 2016.
4. [4] Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., et al. Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33 (2015), 1688–1696.
5. [5] Ali, N., Allam, H., May, R., Sureban, S.M., Bronze, M.S., Bader, T., et al. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J. Virol. 85 (2011), 12292–12303.
6. [6] Ang, W.X., Li, Z., Chi, Z., Du, S.H., Chen, C., Tay, J.C., et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget, 2017.
7. [7] Bandopadhyay, M., Bulbule, A., Butti, R., Chakraborty, G., Ghorpade, P., Ghosh, P., et al. Osteopontin as a therapeutic target for cancer. Expert Opin. Ther. Target 18 (2014), 883–895.
8. [8] Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2 (2014), 112–120.
9. [9] Bellone, S., Black, J., English, D.P., Schwab, C.L., Lopez, S., Cocco, E., et al. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. Am. J. Obstet. Gynecol. 214:99 (2016), e91–e98.
10. [10] Bohne, F., Chmielewski, M., Ebert, G., Wiegmann, K., Kurschner, T., Schulze, A., et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134 (2008), 239–247.
11. [11] Bohne, F., Hasreiter, J., Quitt, O., Meyer, C., Dhamodaran, A., Alvarez, L., et al. Bispecific antibody constructs mediate immunotherapeutic retargeting of effector cells towards HBV infected target cells. Z. Gastroenterol. 53 (2015), A5–A10.
12. [12] Bosetti, C., Turati, F., La Vecchia, C., Hepatocellular carcinoma epidemiology, best practice & research. Clin. Gastroenterol. 28 (2014), 753–770.
13. [13] Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, J.R., Naranjo, A., et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375 (2016), 2561–2569.
14. [14] Buschow, S.I., Sprengers, D., Woltman, A.M., To target or not to target viral antigens in HBV related HCC?. J. Hepatol. 62 (2015), 1449–1450.
15. [15] Cao, L., Fan, X.Y., Jing, W., Liang, Y.C., Chen, R., Liu, Y.Y., et al. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-kappaB-HIF-1alpha pathway. Oncotarget 6 (2015), 6627–6640.
16. [16] Carrega, P., Bonaccorsi, I., Di Carlo, E., Morandi, B., Paul, P., Rizzello, V., et al. CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J. Immunol. 192 (2014), 3805–3815.
17. [17] Chan, A.W., Tong, J.H., Chan, S.L., Lai, P.B., To, K.F., Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 64 (2014), 935–950.
18. [18] Chen, Q., Sun, P., Prigione, I., Xie, H., Ferrini, S., Targeting of “T” lymphocytes against human hepatoma cells by a bispecific monoclonal antibody: role of different lymphocyte subsets. Tumori 78 (1992), 79–86.
19. [19] Chen, Y., Huang, Y., Reiberger, T., Duyverman, A.M., Huang, P., Samuel, R., et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59 (2014), 1435–1447.
20. [20] Chen, Y., Ramjiawan, R.R., Reiberger, T., Ng, M.R., Hato, T., Huang, Y., et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61 (2015), 1591–1602.
21. [21] Chen, Y., Yu, D.K., Zhang, H., He, H.W., Zhang, C.X., Zhao, W.L., et al. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int. J. Biol. Sci. 8 (2012), 992–1004.
22. [22] Chu, C.M., Liaw, Y.F., Membrane staining for hepatitis B surface antigen on hepatocytes: a sensitive and specific marker of active viral replication in hepatitis B. J. Clin. Pathol. 48 (1995), 470–473.
23. [23] Chuang, W.L., Liu, H.W., Chang, W.Y., Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 65 (1990), 926–930.
24. [24] Couzin-Frankel, J., Breakthrough of the year 2013. Cancer immunotherapy. Science 342 (2013), 1432–1433.
25. [25] Deng, Z., Wu, Y., Ma, W., Zhang, S., Zhang, Y.Q., Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol., 16, 2015, 1.
26. [26] Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365 (2011), 1673–1683.
27. [27] Ding, K., Fan, L., Chen, S., Wang, Y., Yu, H., Sun, Y., et al. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC. Oncol. Rep. 34 (2015), 3297–3303.
28. [28] Ding, T., Xu, J., Wang, F., Shi, M., Zhang, Y., Li, S.P., et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum. Pathol. 40 (2009), 381–389.
29. [29] El-Khoueiry, A.B., Melero, I., Crocenzi, T.S., Welling, T.H., Yau, T.C., Yeo, W., et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209–040. ASCO Annual Meeting Proceedings, 2015, LBA101.
30. [30] El-Serag, H.B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142 (2012), 1264–1273 e1261.
31. [31] English, D.P., Bellone, S., Schwab, C.L., Roque, D.M., Lopez, S., Bortolomai, I., et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 121 (2015), 403–412.
32. [32] Eshhar, Z., Waks, T., Gross, G., Schindler, D.G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 720–724.
33. [33] Ferrara, N., Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004), 581–611.
34. [34] Ferrari, F., Bellone, S., Black, J., Schwab, C.L., Lopez, S., Cocco, E., et al. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE (R)), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J. Exp. Clin. Cancer Res., 34, 2015, 123.
35. [35] Fry, T.J., Stetler-Stevenson, M., Shah, N.N., Yuan, C.M., Yates, B., Delbrook, C., et al. Clinical activity and persistence of anti-CD22 chimeric antigen receptor in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood, 126, 2015 1324–1324.
36. [36] Gao, B., Jeong, W.I., Tian, Z., Liver: an organ with predominant innate immunity. Hepatology 47 (2008), 729–736.
37. [37] Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 20 (2014), 6418–6428.
38. [38] Gao, X.H., Tian, L., Wu, J., Ma, X.L., Zhang, C.Y., Zhou, Y., et al. Circulating CD14+ HLA-DR-/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol. Res. Off. J. Jpn. Soc. Hepatol., 2016.
39. [39] Geng, M., Xin, X., Bi, L.Q., Zhou, L.T., Liu, X.H., Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis. World J. Gastroenterol. 21 (2015), 10732–10738.
40. [40] Goossens, N., Hoshida, Y., Hepatitis C virus-induced hepatocellular carcinoma. Clin. Mol. Hepatol. 21 (2015), 105–114.
41. [41] Gotoh, M., Sakamoto, M., Kanetaka, K., Chuuma, M., Hirohashi, S., Overexpression of osteopontin in hepatocellular carcinoma. Pathol. Int. 52 (2002), 19–24.
42. [42] Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
43. [43] Haraguchi, N., Ishii, H., Mimori, K., Tanaka, F., Ohkuma, M., Kim, H.M., et al. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Investig. 120 (2010), 3326–3339.
44. [44] Hashimoto, K., Perera, A., Ogita, Y., Nakamura, M., Ishiguro, T., Sano, Y., et al. A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors. ASCO Annual Meeting, J Clin Oncol (Suppl; Abstr TPS2592), 2016.
45. [45] He, A.R., Smith, D.C., Mishra, L., Targeting cancer stem cells in hepatocellular carcinoma. Gastrointest. Cancer Targets Ther., 5, 2015.
46. [46] Ho, M., Kim, H., Glypican-3: a new target for cancer immunotherapy. Eur. J. Cancer 47 (2011), 333–338.
47. [47] Hoh, A., Dewerth, A., Vogt, F., Wenz, J., Baeuerle, P.A., Warmann, S.W., et al. The activity of gamma delta T cells against paediatric liver tumour cells and spheroids in cell culture. Liver Int. 33 (2013), 127–136.
48. [48] Hsu, H.C., Cheng, W., Lai, P.L., Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 57 (1997), 5179–5184.
49. [49] Ishiyama, K., Ohdan, H., Ohira, M., Mitsuta, H., Arihiro, K., Asahara, T., Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 43 (2006), 362–372.
50. [50] Jochems, C., Schlom, J., Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp. Biol. Med. 236 (2011), 567–579.
51. [51] Kalathil, S.G., Lugade, A.A., Miller, A., Iyer, R., Thanavala, Y., PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight, 1, 2016.
52. [52] Kanat, O., Gewirtz, A., Kemeny, N., What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer. J. Gastrointest. Oncol. 3 (2012), 130–138.
53. [53] Katz, S.C., Burga, R.A., McCormack, E., Wang, L.J., Mooring, W., Point, G.R., et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 21 (2015), 3149–3159.
54. [54] Kinoshita, Y., Tanaka, S., Souzaki, R., Miyoshi, K., Kohashi, K., Oda, Y., et al. Glypican 3 expression in pediatric malignant solid tumors. Eur. J. Pediatr. Surg. 25 (2015), 138–143.
55. [55] Koh, S., Shimasaki, N., Suwanarusk, R., Ho, Z.Z., Chia, A., Banu, N., et al. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol. Ther-Nucl. Acids, 2, 2013.
56. [56] Korita, P.V., Wakai, T., Shirai, Y., Matsuda, Y., Sakata, J., Cui, X., et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum. Pathol. 39 (2008), 1777–1783.
57. [57] Kou, G., Shi, J., Chen, L., Zhang, D., Hou, S., Zhao, L., et al. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett. 299 (2010), 130–136.
58. [58] Krebs, K., Bottinger, N., Huang, L.R., Chmielewski, M., Arzberger, S., Gasteiger, G., et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145 (2013), 456–465.
59. [59] Le Trinh, T., Wu, Q., Chang, L.-J., Ho, M., Liu, C., Abstract 2316: GPC3-specific chimeric antigen receptor T cell in combination with Sorafenib as a novel therapeutic treatment for hepatocellular carcinoma. Cancer Res., 76, 2016 2316–2316.
60. [60] Lee, T.K.W., Castilho, A., Cheung, V.C.H., Tang, K.H., Ma, S., Irene, O.L.N., CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9 (2011), 50–63.
61. [61] Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56 (2012), 1342–1351.
62. [62] Li, J., Gao, J.Z., Du, J.L., Wei, L.X., Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. World J. Gastroenterol. 20 (2014), 6336–6344.
63. [63] Li, K., Pan, X., Bi, Y., Xu, W., Chen, C., Gao, H., et al. Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget 7 (2016), 2496–2507.
64. [64] Li, W., Guo, L., Rathi, P., Marinova, E., Gao, X., Wu, M.F., et al. Redirecting T cells to Glypican-3 with 4-1BB.zeta CAR results in Th-1 polarization and potent anti-tumor activity. Hum. Gene Ther., 2016.
65. [65] Li, W., Guo, L., Rathi, P., Marinova, E., Gao, X., Wu, M.F., et al. Redirecting T cells to Glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity. Hum. Gene Ther., 2016.
66. [66] Liang, X., Bi, S., Yang, W., Wang, L., Cui, G., Cui, F., et al. Reprint of: epidemiological serosurvey of Hepatitis B in China–declining HBV prevalence due to Hepatitis B vaccination. Vaccine 31:Suppl. 9 (2013), J21–J28.
67. [67] Liao, Y., Tang, Z., Liu, K., Ye, S., Li, J., Huang, Z., et al. Preparation and application of anti-HBx/anti-CD3 bispecific monoclonal antibody (BsAb) retargeting effector cells for lysis of human hepatoma xenografts in nude mice. Oncol. Rep. 3 (1996), 637–644.
68. [68] Lin, F., Li, Y.Y., Cao, J., Fan, S.F., Wen, J.F., Zhu, G.H., et al. Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol. Biol. Rep. 38 (2011), 5205–5210.
69. [69] Liu, H., Xu, Y., Xiang, J., Long, L., Green, S., Yang, Z., et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2016.
70. [70] Liu, R., Shen, Y., Nan, K., Mi, B., Wu, T., Guo, J., et al. Association between expression of cancer stem cell markers and poor differentiation of hepatocellular carcinoma: a meta-analysis (PRISMA). Medicine, 94, 2015, e1306.
71. [71] Liu, X., Wang, S.K., Zhang, K., Zhang, H., Pan, Q., Liu, Z., et al. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers. Carcinogenesis 36 (2015), 232–242.
72. [72] Lok, A.S., McMahon, B.J., Brown, R.S. Jr., Wong, J.B., Ahmed, A.T., Farah, W., et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63 (2016), 284–306.
73. [73] Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118 (2011), 6050–6056.
74. [74] Mackall, C.L., Merchant, M.S., Fry, T.J., Immune-based therapies for childhood cancer. Nat. Rev. Clin. Oncol. 11 (2014), 693–703.
75. [75] Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
76. [76] Mayer, K., Baumann, A.L., Grote, M., Seeber, S., Kettenberger, H., Breuer, S., et al. TriFabs–trivalent IgG-shaped bispecific antibody derivatives: design, generation, characterization and application for targeted payload delivery. Int. J. Mol. Sci. 16 (2015), 27497–27507.
77. [77] Mima, K., Okabe, H., Ishimoto, T., Hayashi, H., Nakagawa, S., Kuroki, H., et al. CD44s regulates the TGF-beta-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 72 (2012), 3414–3423.
78. [78] Miura, H., Miyazaki, T., Kuroda, M., Oka, T., Machinami, R., Kodama, T., et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol. 27 (1997), 854–861.
79. [79] Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
80. [80] Nakatsura, T., Yoshitake, Y., Senju, S., Monji, M., Komori, H., Motomura, Y., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophs. Res. Co. 306 (2003), 16–25.
81. [81] Newick, K., O'Brien, S., Moon, E., Albelda, S.M., CAR T cell therapy for solid tumors. Annu. Rev. Med. 68 (2017), 139–152.
82. [82] Patriarca, C., Macchi, R.M., Marschner, A.K., Mellstedt, H., Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat. Rev. 38 (2012), 68–75.
83. [83] Petrelli, F., Borgonovo, K., Lonati, V., Elia, S., Barni, S., Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Target Oncol. 8 (2013), 291–294.
84. [84] Petsch, S., Gires, O., Ruttinger, D., Denzel, S., Lippold, S., Baeuerle, P.A., et al. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. Mabs-Austin, vol. 3, 2011, 31–37.
85. [85] Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med., 7, 2015 303ra139.
86. [86] Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
87. [87] Ramchandani, D., Weber, G.F., Interactions between osteopontin and vascular endothelial growth factor: implications for cancer. Biochim. Biophys. Acta 1855 (2015), 202–222.
88. [88] Robbins, P.F., Morgan, R.A., Feldman, S.A., Yang, J.C., Sherry, R.M., Dudley, M.E., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29 (2011), 917–924.
89. [89] Rosenberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86 (1994), 1159–1166.
90. [90] Sahm, C., Schonfeld, K., Wels, W.S., Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol. Immunother. CII 61 (2012), 1451–1461.
91. [91] Saijyo, S., Kudo, T., Katayose, Y., Saeki, H., Chiba, N., Suzuki, M., et al. A new in vitro model of specific targeting therapy of cancer: retargeting of PWM-LAK cells with bispecific antibodies greatly enhances cytotoxicity to hepatocellular carcinoma. Tohoku J. Exp. Med. 178 (1996), 113–127.
92. [92] Sautto, G.A., Wisskirchen, K., Clementi, N., Castelli, M., Diotti, R.A., Graf, J., et al. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut 65 (2016), 512–523.
93. [93] Seeber, A., Martowicz, A., Spizzo, G., Buratti, T., Obrist, P., Fong, D., et al. Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro. Bmc Cancer, 15, 2015.
94. [94] Seimetz, D., Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J. Cancer 2 (2011), 309–316.
95. [95] Shang, S.F., Plymoth, A., Ge, S.K., Feng, Z.D., Rosen, H.R., Sangrajrang, S., et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55 (2012), 483–490.
96. [96] Shi, F., Shi, M., Zeng, Z., Qi, R.Z., Liu, Z.W., Zhang, J.Y., et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer 128 (2011), 887–896.
97. [97] Soga, N., Connolly, J.O., Chellaiah, M., Kawamura, J., Hruska, K.A., Rac regulates vascular endothelial growth factor stimulated motility. Cell Commun. Adhes. 8 (2001), 1–13.
98. [98] Sun, T.W., Gao, Q., Qiu, S.J., Zhou, J., Wang, X.Y., Yi, Y., et al. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol. Immunother. CII 61 (2012), 2171–2182.
99. [99] Sun, Y.F., Xu, Y., Yang, X.R., Guo, W., Zhang, X., Qiu, S.J., et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57 (2013), 1458–1468.
100. [100] Sung, J.J., Noh, S.J., Bae, J.S., Park, H.S., Jang, K.Y., Chung, M.J., et al. Immunohistochemical expression and clinical significance of suggested stem cell markers in hepatocellular carcinoma. J. Pathol. Transl. Med., 2015.
101. [101] Tarocchi, M., Polvani, S., Marroncini, G., Galli, A., Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J. Gastroenterol. 20 (2014), 11630–11640.
102. [102] Terris, B., Cavard, C., Perret, C., EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J. Hepatol. 52 (2010), 280–281.
103. [103] Truong, P., Rahal, A., Kallail, K.J., Metastatic hepatocellular carcinoma responsive to pembrolizumab. Cureus, 8, 2016, e631.
104. [104] Tu, J.F., Ding, Y.H., Ying, X.H., Wu, F.Z., Zhou, X.M., Zhang, D.K., et al. Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci. Rep., 6, 2016, 35056.
105. [105] Vannini, N., Roch, A., Naveiras, O., Griffa, A., Kobel, S., Lutolf, M.P., Identification of in vitro HSC fate regulators by differential lipid raft clustering. Cell Cycle 11 (2012), 1535–1543.
106. [106] von Marschall, Z., Cramer, T., Hocker, M., Finkenzeller, G., Wiedenmann, B., Rosewicz, S., Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48 (2001), 87–96.
107. [107] Xiao, X., Lao, X.M., Chen, M.M., Liu, R.X., Wei, Y., Ouyang, F.Z., et al. PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6 (2016), 546–559.
108. [108] Xu, X., Liu, R.F., Zhang, X., Huang, L.Y., Chen, F., Fei, Q.L., et al. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol. Cancer Ther. 11 (2012), 629–638.
109. [109] Yamashita, T., Forgues, M., Wang, W., Kim, J.W., Ye, Q., Jia, H., et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68 (2008), 1451–1461.
110. [110] Yamashita, T., Honda, M., Nakamoto, Y., Baba, M., Nio, K., Hara, Y., et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 57 (2013), 1484–1497.
111. [111] Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H.Y., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136 (2009), 1012–1024.
112. [112] Yan, X.L., Jia, Y.L., Chen, L., Zeng, Q., Zhou, J.N., Fu, C.J., et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 57 (2013), 2274–2286.
113. [113] Yang, W., Wang, C., Lin, Y., Liu, Q., Yu, L.X., Tang, L., et al. OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J. Hepatol. 57 (2012), 613–620.
114. [114] Yang, X.R., Xu, Y., Yu, B., Zhou, J., Qiu, S.J., Shi, G.M., et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59 (2010), 953–962.
115. [115] Yang, Z.F., Ho, D.W., Ng, M.N., Lau, C.K., Yu, W.C., Ngai, P., et al. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell 13 (2008), 153–166.
116. [116] Yin, S.Y., Li, J.J., Hu, C., Chen, X.H., Yao, M., Yan, M.X., et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 120 (2007), 1444–1450.
117. [117] Ying, X., Zhao, Y., Wang, J.L., Zhou, X., Zhao, J., He, C.C., et al. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. Oncol. Rep. 32 (2014), 1550–1556.
118. [118] Zhang, P., Shi, B., Gao, H., Jiang, H., Kong, J., Yan, J., et al. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. Cancer Immunol. Immunother. CII 63 (2014), 121–132.
119. [119] Zhu, Z., Hao, X.F., Yan, M.X., Yao, M., Ge, C., Gu, J.R., et al. Cancer stem/progenitor cells are highly enriched in CD133(+)CD44(+) population in hepatocellular carcinoma. Int. J. Cancer 126 (2010), 2067–2078.